Longeveron vs Neurogene
LGVN and NGNE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LGVN and NGNE compare
Neurogene is the larger company, worth 6.9 times as much as Longeveron ($462M against $67.3M).
Neurogene scores higher on the StockData Score (7 against 5 for Longeveron), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LGVN | NGNE |
|---|---|---|
| Size and price | ||
| Market cap | $67.3M | $462M |
| Share price | $2.11 | $23.10 |
| Change, 1 year | −69.0% | 1.4% |
| Change, 5 years | −99.9% | −77.4% |
| Beta (5Y) | 1.44 | 2.01 |
| Employees | 37 | 131 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 56.7× | – |
| P/B | 6.5× | 2.1× (better) |
| FCF yield | −30.5% | −19.0% (better) |
| Growth | ||
| Revenue growth (TTM) | −42.7% | – |
| Revenue growth, 5Y average | −26.6% | – |
| Profitability | ||
| Gross margin | 69.8% | – |
| Operating margin | −1993% | – |
| Net margin | −1978% | – |
| FCF margin | −1730% | – |
| Return on equity | −204% | −45.3% (better) |
| Return on invested capital | −1412% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −60673.0× |
| Current ratio | 2.63 | 10.64 (better) |
| Altman Z-score | −9.42 | 7.17 (better) |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 1.5% | 86.5% |
| Held by insiders | 43.8% | 15.9% |
| Insider net buying, 12 months | – | −$1.1M |
| Short interest, % of float | 0.88% | 33.8% |
Go deeper
- LGVN stock overview
- LGVN income statement
- LGVN valuation and score
- NGNE stock overview
- NGNE income statement
- NGNE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.